Search

Displaying results 2931 - 2940 of 7687 in total
  1. Drug

    Epicept NP-1

    go.drugbank.com/drugs/DB05492
    Investigational

    EpiCept NP-1 Cream is a patented formulation containing two FDA-approved drugs, amitriptyline (a widely-used antidepressant) and ketamine (an NMDA antagonist that is used as an anesthetic).

  2. Drug

    Denifanstat

    go.drugbank.com/drugs/DB17576
    Investigational

    Denifanstat is an orally bioavailable fatty acid synthase (FASN) inhibitor. Due to its antineoplastic activities, it is being investigated for various cancers.

  3. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

  4. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction. … Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D).

  5. Drug

    Anthrax immune globulin human

    go.drugbank.com/drugs/DB09057
    ApprovedInvestigational

    Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and

  6. Drug

    RGN6024

    go.drugbank.com/drugs/DB33059
    Experimental

    Reglagene announced FDA orphan drug designation for glioblastoma in 2024. RGN6024 remains investigational and is not an approved drug. … It is designed as an orally administered, blood-brain barrier penetrant therapy for brain cancers, especially glioblastoma.

  7. Drug

    Calcitonin gene-related peptide

    go.drugbank.com/drugs/DB06379
    Investigational

    As a potential drug, it has demonstrated in preclinical studies a profile that could make it an ideal anti-asthmatic drug candidate with bronchodilatory, bronchoprotecting and anti-inflammatory properties

  8. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. … [A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular

  9. Drug

    Fenoterol

    go.drugbank.com/drugs/DB01288
    ApprovedWithdrawn

    Fenoterol is an adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.

  10. Drug

    CYT006-AngQb

    go.drugbank.com/drugs/DB05739
    Investigational

    It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination. … It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure